Private Advisor Group LLC bought a new position in Athenex Inc (NASDAQ:ATNX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 16,100 shares of the company’s stock, valued at approximately $250,000.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. BlackRock Inc. raised its holdings in shares of Athenex by 106.3% during the second quarter. BlackRock Inc. now owns 3,472,246 shares of the company’s stock valued at $64,793,000 after buying an additional 1,789,061 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Athenex by 249.8% during the second quarter. Northern Trust Corp now owns 511,476 shares of the company’s stock valued at $9,545,000 after buying an additional 365,240 shares during the last quarter. Northpointe Capital LLC bought a new stake in shares of Athenex during the third quarter valued at approximately $2,540,000. Citadel Advisors LLC bought a new stake in shares of Athenex during the second quarter valued at approximately $2,258,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Athenex by 177.9% during the second quarter. Bank of New York Mellon Corp now owns 163,893 shares of the company’s stock valued at $3,058,000 after buying an additional 104,918 shares during the last quarter. 20.93% of the stock is currently owned by hedge funds and other institutional investors.
In other news, CEO Johnson Yiu Nam Lau bought 5,000 shares of the company’s stock in a transaction that occurred on Thursday, September 6th. The shares were purchased at an average price of $15.84 per share, with a total value of $79,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,825,422 shares in the company, valued at $44,754,684.48. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jeffrey Yordon bought 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, November 14th. The shares were purchased at an average cost of $10.49 per share, for a total transaction of $99,655.00. Following the acquisition, the insider now owns 198,209 shares of the company’s stock, valued at $2,079,212.41. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 93,500 shares of company stock worth $1,081,935. 29.50% of the stock is owned by corporate insiders.
ATNX opened at $13.22 on Friday. The company has a market cap of $873.63 million, a PE ratio of -5.70 and a beta of 0.31. The company has a current ratio of 4.46, a quick ratio of 3.86 and a debt-to-equity ratio of 0.30. Athenex Inc has a twelve month low of $9.83 and a twelve month high of $20.90.
Athenex (NASDAQ:ATNX) last released its quarterly earnings results on Wednesday, November 14th. The company reported ($0.33) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.12. The company had revenue of $18.43 million for the quarter. Athenex had a negative return on equity of 71.94% and a negative net margin of 143.42%. As a group, analysts anticipate that Athenex Inc will post -1.98 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This article was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.com-unik.info/2018/12/01/private-advisor-group-llc-buys-shares-of-16100-athenex-inc-atnx.html.
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.
See Also: What does relative strength index mean?
Want to see what other hedge funds are holding ATNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athenex Inc (NASDAQ:ATNX).
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.